Conor MacKay
Stock Analyst at BMO Capital
(1.63)
# 3,519
Out of 4,646 analysts
5
Total ratings
40%
Success rate
1.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Conor MacKay
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Reiterated: Buy | $192 | $126.33 | +51.98% | 2 | Aug 6, 2026 | |
| NAMS NewAmsterdam Pharma Company | Rated: Buy | $58 | $26.67 | +117.47% | 2 | Aug 5, 2026 | |
| TRVI Trevi Therapeutics | Initiated Coverage: Buy | $36 | $18.15 | +98.35% | 1 | Jul 21, 2026 |
Insmed
Aug 6, 2026
Reiterated: Buy
Price Target: $192
Current: $126.33
Upside: +51.98%
NewAmsterdam Pharma Company
Aug 5, 2026
Rated: Buy
Price Target: $58
Current: $26.67
Upside: +117.47%
Trevi Therapeutics
Jul 21, 2026
Initiated Coverage: Buy
Price Target: $36
Current: $18.15
Upside: +98.35%